SCHEMBL6978552

SCHEMBL6978552

COc1ccc2nc(-c3ccccc3)c[c]c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.57
SMN1; SMN2 Q16637 7/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
ACACA Q13085 1/20 0.54
ALDH1A1 P00352 6/20 0.52
NPC1 O15118 5/20 0.50
RAB9A P51151 5/20 0.50
LMNA P02545 4/20 0.50
HPGD P15428 4/20 0.50
MAPT P10636 3/20 0.50
NQO2 P16083 2/20 0.50
HTT P42858 1/20 0.50
POLB P06746 1/20 0.50
PLA2G2A P14555 1/20 0.50
AURKA O14965 1/20 0.48
AURKB Q96GD4 1/20 0.48
NFKB1 P19838 3/20 0.47
NFKB2 Q00653 3/20 0.47
RELA Q04206 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2215511 0.88 KDM4E (0.56) KDM4ESMN1; SMN2MEN1KMT2AACACA
SCHEMBL29210421 0.87 ACP1 (0.46) KDM4ESMN1; SMN2MEN1KMT2AACACA
SCHEMBL4909955 0.82 KDM4E (0.58) KDM4ESMN1; SMN2ACACAALDH1A1NPC1
SCHEMBL16538745 0.76 POLB (0.49) KDM4ESMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL234452 0.76 ACHE (0.47) KDM4ESMN1; SMN2MEN1KMT2AACACA
SCHEMBL5682765 0.75 KDM4E (0.66) KDM4ESMN1; SMN2MEN1KMT2AACACA
SCHEMBL30228475 0.75 KDM4E (0.66) KDM4ESMN1; SMN2MEN1KMT2AACACA
SCHEMBL28350370 0.74 KDM4E (0.75) KDM4ESMN1; SMN2MEN1KMT2AACACA
SCHEMBL30064616 0.74 KDM4E (0.75) KDM4ESMN1; SMN2MEN1KMT2AACACA
SCHEMBL3463591 0.73 KDM4E (0.68) KDM4ESMN1; SMN2MEN1KMT2AACACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6562964-B1 Inhibitors of rotamase enzymes in particular FKBP-12 and FKBP-52. The compounds therefore moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases or other disorders PFIZER INC 2003-05-13 US disclosed
EP-1100797-B1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES PFIZER LTD (GB) 2003-02-26 EP disclosed
US-6372736-B1 ENZYME INHIBITORS PFIZER INC 2002-04-16 US disclosed
EP-1100797-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES Pfizer Limited (GB) 2001-05-23 EP disclosed
WO-2000005232-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES PFIZER LIMITED (GB) 2000-02-03 WO disclosed